3 research outputs found
Palladium-Catalyzed <i>ortho</i>–C‑H Arylation of Acetophenone Oxime Ethers with Aryl Pinacol Boronic Esters
We
report an efficient palladium-catalyzed <i>ortho</i>–C-H
arylation of acetophenone oxime ethers with aryl pinacol
boronic esters, leading to the synthesis of biaryl derivatives in
good yields. Sequential process of iridium-catalyzed C–H borylation
and palladium-catalyzed <i>ortho</i>–C-H arylation
directed to access functionalized arenes
Synthesis of Aryl Thioethers through the <i>N</i>‑Chlorosuccinimide-Promoted Cross-Coupling Reaction of Thiols with Grignard Reagents
A convenient one-pot approach for the synthesis of aryl
sulfides
through the coupling of thiols with Grignard reagents in the presence
of <i>N</i>-chlorosuccinimide is described. The sulfenylchlorides
were formed when thiols were treated with <i>N</i>-chlorosuccinimide,
and the resulting sulfenylchlorides were then directly reacted with
Grignard reagents to provide aryl sulfides in good to excellent yields
under mild reaction conditions. Functional groups including ester,
fluoro, and chloro are tolerated by the reaction conditions employed.
It is important to note that this method has a short reaction time
(30 min in total) and represents an alternative approach for the synthesis
of aryl sulfides over the existing protocols
Cross-Linked Fluorescent Supramolecular Nanoparticles for Intradermal Controlled Release of Antifungal Drugî—¸A Therapeutic Approach for Onychomycosis
The existing approaches to onychomycosis
demonstrate limited success
since the commonly used oral administration and topical cream only
achieve temporary effective drug concentration at the fungal infection
sites. An ideal therapeutic approach for onychomycosis should have
(i) the ability to introduce antifungal drugs directly to the infected
sites; (ii) finite intradermal sustainable release to maintain effective
drug levels over prolonged time; (iii) a reporter system for monitoring
maintenance of drug level; and (iv) minimum level of inflammatory
responses at or around the fungal infection sites. To meet these expectations,
we introduced ketoconazole-encapsulated cross-linked fluorescent supramolecular
nanoparticles (KTZ⊂c-FSMNPs) as an intradermal controlled release
solution for treating onychomycosis. A two-step synthetic approach
was adopted to prepare a variety of KTZ⊂c-FSMNPs. Initial characterization
revealed that 4800 nm KTZ⊂c-FSMNPs exhibited high KTZ encapsulation
efficiency/capacity, optimal fluorescent property, and sustained KTZ
release profile. Subsequently, 4800 nm KTZ⊂c-FSMNPs were chosen
for <i>in vivo</i> studies using a mouse model, wherein the KTZ⊂c-FSMNPs were deposited intradermally <i>via</i> tattoo. The results obtained from (i) <i>in vivo</i> fluorescence imaging, (ii) high-performance liquid chromatography quantification of residual KTZ, (iii) matrix-assisted laser desorption/ionization mass spectrometry imaging mapping of KTZ distribution in intradermal regions around the tattoo site, and (iv) histology for assessment of local inflammatory responses and biocompatibility, suggest that 4800 nm KTZ⊂c-FSMNPs can serve as an effective treatment for onychomycosis